We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.42 | -0.64% | 65.09 | 65.11 | 65.40 | 65.80 | 64.89 | 65.75 | 5,571,501 | 00:55:03 |
From May 2019 to May 2024
By Stephen Nakrosis
Gilead Sciences, Inc. on Tuesday said the Food and Drug Administration granted accelerated approval to Trodelvy to treat certain adult patients with metastatic urothelial cancer.
The accelerated approval for Trodelvy, or sacituzumab govitecan-hziy, is for the treatment of "adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor," Gilead said.
The new indication marks the second FDA approval for Trodelvy this year, according to Gilead.
The FDA said the Accelerated Approval Program allows "for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 13, 2021 18:39 ET (22:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
